Oragenics announced that it has raised approximately $16.5 million in a Series H funding round, with proceeds going toward repayment of a $3 million bridge loan and continued development of the company’s OPN-002 neurosteroid nasal powder for the treatment of mild traumatic brain injury. Oragenics recently announced that it had submitted an application to Australian authorities for permission to conduct a Phase 2 trial of ONP-002.
The intranasal therapy (formerly PRV-002) was previously developed by Prevacus and acquired by Odyssey Health in 2021. Oragenics acquired ONP-002 from Odyssey in 2023. Oragenics has also worked on development of an intranasal COVID-19 vaccine (NT-CoV-2).
Oragenics CEO Janet Huffman commented, “We are pleased to have completed this transaction and are encouraged by the strong investor support, which we believe reflects growing confidence in our science and strategy. We anticipate the net proceeds of this offering will allow us to accelerate the advancement of ONP-002 and position Oragenics as a leader in the treatment of concussion through novel intranasal delivery.”
Read the Oragenics press release
